ATE244018T1 - Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer - Google Patents
Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimerInfo
- Publication number
- ATE244018T1 ATE244018T1 AT96903108T AT96903108T ATE244018T1 AT E244018 T1 ATE244018 T1 AT E244018T1 AT 96903108 T AT96903108 T AT 96903108T AT 96903108 T AT96903108 T AT 96903108T AT E244018 T1 ATE244018 T1 AT E244018T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- alzheimer
- disease
- receptor ligand
- aalpha5
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- 230000019771 cognition Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9426—GABA, i.e. gamma-amino-butyrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9503601.8A GB9503601D0 (en) | 1995-02-23 | 1995-02-23 | Method of treatment and method of manufacture of medicament |
| PCT/GB1996/000377 WO1996025948A1 (en) | 1995-02-23 | 1996-02-20 | PREPARATION AND USE OF A SPECIFIC GABA-Aα5 RECEPTOR LIGAND FOR TREATMENT OF ALZHEIMER'S DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE244018T1 true ATE244018T1 (de) | 2003-07-15 |
Family
ID=10770108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96903108T ATE244018T1 (de) | 1995-02-23 | 1996-02-20 | Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6426343B1 (de) |
| EP (1) | EP0810879B1 (de) |
| JP (1) | JPH11501302A (de) |
| AT (1) | ATE244018T1 (de) |
| AU (1) | AU706515B2 (de) |
| CA (1) | CA2212058C (de) |
| DE (1) | DE69628912T2 (de) |
| ES (1) | ES2201169T3 (de) |
| GB (1) | GB9503601D0 (de) |
| WO (1) | WO1996025948A1 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2288789C (en) | 1997-05-08 | 2009-07-21 | Merck Sharp & Dohme Limited | Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands |
| GB9716344D0 (en) * | 1997-08-01 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic compounds |
| CZ291302B6 (cs) | 1998-02-25 | 2003-01-15 | Merck Sharp & Dohme Limited | Substituovaný 1,2,4-triazolo[3,4-a]ftalazinový derivát |
| GB9805559D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| GB9805557D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| GB9805561D0 (en) * | 1998-03-16 | 1998-05-13 | Merck Sharp & Dohme | A combination of therapeutic agents |
| AU1816900A (en) | 1998-11-12 | 2000-05-29 | Merck & Co., Inc. | Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same |
| WO2000027382A2 (en) * | 1998-11-12 | 2000-05-18 | Merck & Co., Inc. | Combination of a gaba-a alpha 5 inverse agonist and cox-2 inhibitor, nsaid, estrogen or vitamin e |
| GB9824897D0 (en) * | 1998-11-12 | 1999-01-06 | Merck Sharp & Dohme | Therapeutic compounds |
| US6737242B1 (en) | 1999-05-07 | 2004-05-18 | Neurogen Corporation | Methods for screening GABA-modulatory compounds for specified pharmacological activities |
| AU4703200A (en) * | 1999-05-07 | 2000-11-21 | Neurogen Corporation | Methods for screening gaba-modulatory compounds for specified pharmacological activities |
| GB9911804D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911802D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911803D0 (en) * | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| IL145209A0 (en) | 2000-09-06 | 2002-06-30 | Pfizer Prod Inc | Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| GB0028583D0 (en) | 2000-11-23 | 2001-01-10 | Merck Sharp & Dohme | Therapeutic compounds |
| US20040023952A1 (en) * | 2001-06-20 | 2004-02-05 | Leventhal Audie G. | Enhanced brain function by gaba-ergic stimulation |
| GB0128499D0 (en) * | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス，インコーポレイティド | Ｐｄｅ阻害による神経新生の調節 |
| EP2314289A1 (de) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| CA2651862A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| ES2573733T3 (es) * | 2006-05-22 | 2016-06-09 | The Board Of Trustees Of The Leland Stanford Junior University | Tratamiento farmacológico del deterioro cognitivo |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2298296A1 (de) | 2009-08-25 | 2011-03-23 | CNRS Centre National De La Recherche Scientifique | Zusammensetzung und Behandlung kognitiver Beeinträchtigungen bei Personen mit Down-Syndrom |
| US8946206B2 (en) | 2010-12-17 | 2015-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for improving cognitive function |
| RU2013139247A (ru) | 2011-02-23 | 2015-03-27 | Церулеус Лтд. | Комплексы флумазенила, содержащие их композиции и их применения |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| KR101743960B1 (ko) * | 2015-07-06 | 2017-06-08 | 서울대학교산학협력단 | G단백질 결합형 수용체19 작용제를 유효성분으로 함유하는 알츠하이머 질환 또는 치매를 예방, 치료 또는 지연하기 위한 약학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU587802B2 (en) * | 1985-03-08 | 1989-08-31 | Ferrosan A/S | Novel oxadiazolyl imidazobenzodiazepine derivatives and methods of preparing such compounds |
| FR2672602B1 (fr) * | 1991-02-12 | 1993-06-04 | Centre Nat Rech Scient | Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant. |
| US5182290A (en) | 1991-08-27 | 1993-01-26 | Neurogen Corporation | Certain oxazoloquinolinones; a new class of GABA brain receptor ligands |
| US5212310A (en) | 1991-12-19 | 1993-05-18 | Neurogen Corporation | Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands |
| US5652100A (en) | 1992-12-10 | 1997-07-29 | Merck Sharpe & Dohme Ltd. | Stably transfected rodent fibroblast cell lines expressing human GABA-A -receptors |
-
1995
- 1995-02-23 GB GBGB9503601.8A patent/GB9503601D0/en active Pending
-
1996
- 1996-02-20 US US08/894,031 patent/US6426343B1/en not_active Expired - Fee Related
- 1996-02-20 AU AU47257/96A patent/AU706515B2/en not_active Ceased
- 1996-02-20 JP JP8525484A patent/JPH11501302A/ja not_active Withdrawn
- 1996-02-20 AT AT96903108T patent/ATE244018T1/de not_active IP Right Cessation
- 1996-02-20 DE DE69628912T patent/DE69628912T2/de not_active Expired - Fee Related
- 1996-02-20 CA CA002212058A patent/CA2212058C/en not_active Expired - Fee Related
- 1996-02-20 ES ES96903108T patent/ES2201169T3/es not_active Expired - Lifetime
- 1996-02-20 WO PCT/GB1996/000377 patent/WO1996025948A1/en not_active Ceased
- 1996-02-20 EP EP96903108A patent/EP0810879B1/de not_active Expired - Lifetime
-
2000
- 2000-07-20 US US09/621,319 patent/US6323198B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69628912D1 (de) | 2003-08-07 |
| CA2212058A1 (en) | 1996-08-29 |
| EP0810879A1 (de) | 1997-12-10 |
| AU706515B2 (en) | 1999-06-17 |
| GB9503601D0 (en) | 1995-04-12 |
| EP0810879B1 (de) | 2003-07-02 |
| JPH11501302A (ja) | 1999-02-02 |
| WO1996025948A1 (en) | 1996-08-29 |
| DE69628912T2 (de) | 2004-06-03 |
| AU4725796A (en) | 1996-09-11 |
| ES2201169T3 (es) | 2004-03-16 |
| US6426343B1 (en) | 2002-07-30 |
| US6323198B1 (en) | 2001-11-27 |
| CA2212058C (en) | 2008-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE244018T1 (de) | Herstellungb und verwendung eines spezifischen gaba-aalpha5 rezeptorligands zur behandlung der erkrankung von alzheimer | |
| DE59600309D1 (de) | Vorrichtung zur Behandlung von Flüssigkeiten, insbesondere von Blut | |
| DE69333348D1 (de) | Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten | |
| DE69609868D1 (de) | Neue steroidester zur behandlung von hauterkrankungen | |
| DE69528475D1 (de) | Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie | |
| GR3033138T3 (en) | Process and compounds for the magnetorelaxometric detection of analytes and use thereof | |
| DE69631157D1 (de) | Pharmazeutische Zubereitung zur Verwendung in der Behandlung von Diabetes | |
| DE69633717D1 (de) | Monoklonale anti-cd6 antikörper zur behandlung und diagnose von psoriasis | |
| DE69124293D1 (de) | Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen | |
| DE69822665D1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| TR199902803T2 (xx) | VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar. | |
| DE3856594D1 (de) | Mittel zur behandlung der alzheimer-krankheit | |
| DE69525279D1 (de) | Behandlung von Leder zum Einfärben desselben, sowie gefärbtes Leder | |
| DE69509843D1 (de) | Apparat zur Behandlung z.B. von Poststücken | |
| DE69013880D1 (de) | Verfahren und Vorrichtung zur Behandlung von Absorptionssuspensionen, die Flugasche beinhalten. | |
| DE69003009D1 (de) | Verfahren zur Behandlung von Fasermaterialien. | |
| ATE221763T1 (de) | Die verwendung von glyceryltriacetat zur behandlung von onychomykosen | |
| DE3781923D1 (de) | Verfahren und vorrichtung zur herstellung von heissem eisenschwamm. | |
| DE69109427D1 (de) | Blockcopolymerdispersionen und Verfahren zur Herstellung von Blockcopolymerdispersionen. | |
| DE69007486D1 (de) | Verwendung von calciumantagonisten für die behandlung von narben. | |
| DE69805305D1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| DE59008012D1 (de) | Mittel zur Behandlung von Leder und Pelzen. | |
| DE69517191D1 (de) | Wasserlösliche derivate epipodophyllotoxine, verfahren zu ihrer herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels | |
| DE69832722D1 (de) | L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen | |
| DE59003390D1 (de) | Verfahren zur Herstellung von Butandiol-1,4 und Tetrahydrofuran. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |